We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 24% below its sector, cheaper than its peers on earnings.
Anhui Anke Biotechnology (Group) Co., Ltd. is engaged in the research, manufacturing, and global distribution of pharmaceutical goods, serving both domestic Chinese and international markets. Its flagship offerings include Ansomone, a brand of recombinant human growth hormone administered via injection, and the Anterferon line, which comprises recombinant human interferon alpha 2b in various forms such as lyophilized powder, liquid, and prefilled syringes for injection, alongside creams, eye drops, and suppositories. The company also supplies an array of diagnostic kits, including those for detecting anti-sperm antibodies, performing semen leukocyte peroxidase staining, single-use semen processing, sperm hypo-osmotic staining, assessing sperm viability, analyzing sperm morphology, determining sperm acrosin levels, identifying sperm DNA fragmentation, and for leptin and immunohistochemical analyses. Furthermore, their product portfolio extends to adhesive bandages, liquid oral medications, various topical formulations (including creams and ointments), active pharmaceutical ingredients (APIs) derived from peptides, cosmetic and anti-aging treatments, and synthetic pharmaceutical compounds available as powders, dripping pills, and both tablets and capsules. Moreover, Anke Biotechnology offers genetic testing solutions, encompassing kits for autosomal, sex chromosome, and combined autosomal and sex chromosome analyses, along with complete paternity testing packages. They also develop biological immunotherapy treatments for tumors and provide specialized DNA testing services. Established in 2000, the firm's headquarters are situated in Hefei, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 300009.SZ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
